[go: up one dir, main page]

CU23739A1 - Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno - Google Patents

Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno

Info

Publication number
CU23739A1
CU23739A1 CU20080185A CU20080185A CU23739A1 CU 23739 A1 CU23739 A1 CU 23739A1 CU 20080185 A CU20080185 A CU 20080185A CU 20080185 A CU20080185 A CU 20080185A CU 23739 A1 CU23739 A1 CU 23739A1
Authority
CU
Cuba
Prior art keywords
gnrh
hormone
combinations
pharmaceutical composition
mimetics
Prior art date
Application number
CU20080185A
Other languages
English (en)
Inventor
Barrocal Luis Alberto Aguero
More Niurka Oneysi Arteaga
Santana Maria Castro
Aguilera Lesvia Calzada
Saez Yovisleidys Lopez
Aguilar Franklin Fuentes
Fuentes Eddy Emilio Bover
Barranco Jesus Arturo Junco
Perez Hilda Elisa Garay
Acosta Osvaldo Reyes
Nieto Gerardo Enrique Guillen
Baker Roberto Basulto
Vazquez Eulogio Pimentel
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20080185A priority Critical patent/CU23739A1/es
Priority to CA2738993A priority patent/CA2738993C/en
Priority to PCT/CU2009/000007 priority patent/WO2010037352A1/es
Priority to RU2011117301/15A priority patent/RU2537138C2/ru
Priority to KR1020117009872A priority patent/KR101631896B1/ko
Priority to CN200980144572.4A priority patent/CN102209558B/zh
Priority to US13/121,915 priority patent/US8999931B2/en
Priority to MX2011003356A priority patent/MX2011003356A/es
Priority to JP2011529440A priority patent/JP5746970B2/ja
Priority to AU2009298305A priority patent/AU2009298305B2/en
Priority to EP09744314.7A priority patent/EP2335736B1/en
Priority to BRPI0919513A priority patent/BRPI0919513A2/pt
Priority to ES09744314.7T priority patent/ES2612747T3/es
Priority to ZA2011/02652A priority patent/ZA201102652B/en
Publication of CU23739A1 publication Critical patent/CU23739A1/es
Priority to US14/662,482 priority patent/US9364524B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica utilizando combinaciones de la hormona GnRH nativa y/o alguno de sus miméticos, unidos indistintamente por sus extremos amino o carboxilo a una molécula portadora, en un caso por su extremo carboxilo y en el otro por su amino terminal, generando una rápida y potente respuesta inmunológica contra la hormona GnRH endógena que conduce finalmente a la ablación de la GnRH y por tanto del resto de las hormonas involucradas en la cascada GnRH/LH-FSH/Testosterona-(estrógeno) y facilitando la exposición al sistema inmune de un mayor número de epítopes de la GnRH o sus miméticos y minimizando el impedimento estérico que producen los portadores. Esta invención tiene una aplicación directa en la castración de animales de interés económico y animales mascotas, en el control de la fertilidad en humanos, y en el tratamiento de tumores hormonosensibles; de próstata, mama, ovario, endometrio, testículo, hipófisis, glándulas salivales y otros tipos de tumores humanos.
CU20080185A 2008-09-30 2008-09-30 Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno CU23739A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU20080185A CU23739A1 (es) 2008-09-30 2008-09-30 Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
MX2011003356A MX2011003356A (es) 2008-09-30 2009-09-30 Composicion farmaceutica utilizando combinaciones de variantes de la hormona liberadora de la gonadotropinas (gnrh) como inmunogeno.
JP2011529440A JP5746970B2 (ja) 2008-09-30 2009-09-30 ゴナドトロピン放出ホルモン（ｇｎｒｈ）変異体の組合せを免疫原として使用する医薬組成物
RU2011117301/15A RU2537138C2 (ru) 2008-09-30 2009-09-30 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННЫХ ВАРИАНТОВ ГОНАДОТРОПИН-РИЛИЗИНГ-ГОРМОНА (GnRH) В КАЧЕСТВЕ ИММУНОГЕНА
KR1020117009872A KR101631896B1 (ko) 2008-09-30 2009-09-30 면역원으로 성선자극호르몬분비촉진호르몬 결합 변형체를 사용한 약학적 조성물
CN200980144572.4A CN102209558B (zh) 2008-09-30 2009-09-30 使用促性腺激素释放激素(gnrh)组合的变体作为免疫原的药物组合物
US13/121,915 US8999931B2 (en) 2008-09-30 2009-09-30 Pharmaceutical composition using gonadotropin-releasing hormone (GNRH) combined variants as immunogen
CA2738993A CA2738993C (en) 2008-09-30 2009-09-30 Pharmaceutical composition utilising combinations of variants of the gonadotropin-releasing hormone (gnrh) as immunogen
PCT/CU2009/000007 WO2010037352A1 (es) 2008-09-30 2009-09-30 Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh ) como immunógeno
AU2009298305A AU2009298305B2 (en) 2008-09-30 2009-09-30 Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (GnRH) as immunogen
EP09744314.7A EP2335736B1 (en) 2008-09-30 2009-09-30 Pharmaceutical composition utilising combinations of variants of the gonadotropin-releasing hormone (gnrh) as immunogen
BRPI0919513A BRPI0919513A2 (pt) 2008-09-30 2009-09-30 composição farmacêutica e utilização de uma mistura de variantes de gnrh
ES09744314.7T ES2612747T3 (es) 2008-09-30 2009-09-30 Una composición farmacéutica que usa combinaciones de variantes de la Hormona Liberadora de las Gonadotropinas (GnRH) como inmunógeno
ZA2011/02652A ZA201102652B (en) 2008-09-30 2011-04-08 Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
US14/662,482 US9364524B2 (en) 2008-09-30 2015-03-19 Pharmaceutical composition using gonadotropin-releasing hormone (GNRH) combined variants as immunogen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20080185A CU23739A1 (es) 2008-09-30 2008-09-30 Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno

Publications (1)

Publication Number Publication Date
CU23739A1 true CU23739A1 (es) 2011-12-28

Family

ID=41606315

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20080185A CU23739A1 (es) 2008-09-30 2008-09-30 Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno

Country Status (14)

Country Link
US (2) US8999931B2 (es)
EP (1) EP2335736B1 (es)
JP (1) JP5746970B2 (es)
KR (1) KR101631896B1 (es)
CN (1) CN102209558B (es)
AU (1) AU2009298305B2 (es)
BR (1) BRPI0919513A2 (es)
CA (1) CA2738993C (es)
CU (1) CU23739A1 (es)
ES (1) ES2612747T3 (es)
MX (1) MX2011003356A (es)
RU (1) RU2537138C2 (es)
WO (1) WO2010037352A1 (es)
ZA (1) ZA201102652B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4120567C2 (de) 1991-06-21 1996-03-14 Vollmer Werke Maschf Maschine zum mehrstufigen Bearbeiten von Kreissägeblättern
CN102850437A (zh) * 2012-09-12 2013-01-02 上海吉尔多肽有限公司 一种组氨瑞林的合成方法
US11224645B2 (en) * 2015-03-23 2022-01-18 Board Of Regents, The University Of Texas System Glycoconjugate vaccine for leishmaniasis
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CN108047328A (zh) * 2017-12-14 2018-05-18 天津瑞普生物技术股份有限公司 一种GnRH多肽抗原及其用于制备去势疫苗的应用
BR102018068504A2 (pt) * 2018-09-12 2021-11-16 Ouro Fino Saúde Animal Ltda Polipeptídeo quimérico antigênico, construção gênica e composição antigênica para imunocastração de mamíferos não humanos
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4556555A (en) * 1985-01-25 1985-12-03 North Carolina State University Process for the immunological neutering of animals
WO1988005308A1 (en) 1987-01-14 1988-07-28 Commonwealth Scientific And Industrial Research Or Anti reproductive hormone
GB8713240D0 (en) 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
NL8900726A (nl) 1989-03-23 1990-10-16 Stichting Centr Diergeneeskund Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens.
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
CU22627A1 (es) 1996-12-17 2000-12-22 Ct Ingenieria Genetica Biotech Preparado vacunal para la inmuno-castración reversible de mamíferos
JP2001514231A (ja) * 1997-09-03 2001-09-11 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ 動物の避妊又は不妊を行うための組成物及び方法
ATE286511T1 (de) * 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
AU2001259452A1 (en) * 2000-05-05 2001-11-20 Aphton Corporation Chimeric peptide immunogens their preparation and use

Also Published As

Publication number Publication date
CA2738993C (en) 2016-10-11
BRPI0919513A2 (pt) 2016-07-05
AU2009298305A8 (en) 2011-06-09
AU2009298305A1 (en) 2010-04-08
EP2335736B1 (en) 2016-11-02
CN102209558B (zh) 2014-05-14
JP5746970B2 (ja) 2015-07-08
AU2009298305B2 (en) 2013-03-28
WO2010037352A1 (es) 2010-04-08
CN102209558A (zh) 2011-10-05
KR101631896B1 (ko) 2016-06-20
KR20110066205A (ko) 2011-06-16
CA2738993A1 (en) 2010-04-08
US20110250196A1 (en) 2011-10-13
RU2011117301A (ru) 2012-11-10
US9364524B2 (en) 2016-06-14
US20150190491A1 (en) 2015-07-09
ES2612747T3 (es) 2017-05-18
US8999931B2 (en) 2015-04-07
ZA201102652B (en) 2012-01-25
MX2011003356A (es) 2011-08-15
RU2537138C2 (ru) 2014-12-27
EP2335736A1 (en) 2011-06-22
JP2012504151A (ja) 2012-02-16

Similar Documents

Publication Publication Date Title
CU23739A1 (es) Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
TR201903610T4 (tr) Alfa-melanosit uyarici hormonlarin peptid analoglari.
CL2019001129A1 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
BR112019022495A2 (pt) Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação
MX2020012248A (es) Polipeptidos de citocina activables y metodos de uso de los mismos.
PE20181049A1 (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
MX2021011826A (es) Composiciones y combinaciones farmacéuticas que comprenden inhibidores del receptor de andrógenos y usos de estas.
MX2017016863A (es) Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina.
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
UY35712A (es) Anticuerpos anti-prlr y uso de los mismos
MX370356B (es) Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria.
BR112016012538A2 (pt) peptídeos citotóxicos e conjugados dos mesmos
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
CL2021001308A1 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteína de los mismos para su uso como agonistas de lxr.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2018002524A (es) Composicion farmaceutica que contiene, como ingrediente activo, proteina de fusion en la que el peptido de tumor-penetrante y el agente anti-angiogenesis se funden, para prevenir y tratar el cancer o enfermedades relacionadas a la angiogenesis.
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
EA201992612A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
MX2017013171A (es) Conjugados anticuerpo-farmaco de sitio especifico.

Legal Events

Date Code Title Description
FG Grant of patent